The invention provided here creates a new paradigm for the treatment of a variety of conditions where modulation of a BAF complex is desired. The disclosure that follows outlines a strategy for modulating a BAF complex in a cell, and provides effective compounds, pharmaceutical compositions, development strategies, and treatment protocols, and describes many of the ensuing benefits. A new family of BAF complex modulating compounds has been developed based on a new chemical scaffold including a 12-membered macrolactam core structures. Contacting target cells in vitro or in vivo with the compounds and compositions of this invention can selectively inhibit the activity of BAF complexes in such cells. Some of the BAF complex modulating compounds in this family are particularly effective agents for treating cancer in conjunction with a ATR inhibitor.

The invention provided here creates a new paradigm for the treatment of a variety of conditions where modulation of a BAF complex is desired. The disclosure that follows outlines a strategy for modulating a BAF complex in a cell, and provides effective compounds, pharmaceutical compositions, development strategies, and treatment protocols, and describes many of the ensuing benefits. A new family of BAF complex modulating compounds has been developed based on a new chemical scaffold including a 12-membered macrolactam core structures. Contacting target cells in vitro or in vivo with the compounds and compositions of this invention can selectively inhibit the activity of BAF complexes in such cells. Some of the BAF complex modulating compounds in this family are particularly effective agents for treating cancer in conjunction with a ATR inhibitor.

This disclosure provides methods of using BAF complex modulating compounds as inhibitors of BAF-mediated transcription in target cells. The BAF complex modulating compounds include 12-membered macrolactam compounds that can target a BAF-specific subunit (e.g., ARID1A) to prevent nucleosomal positioning, relieving transcriptional repression of HIV-1. The subject methods can provide for reversal of latency of HIV-1 in cells in vitro or in vivo. Use of the macrolactam BAF complex modulating compounds represent a method of HIV latency reversal with a unique mechanism of action, which can be optionally combined with other Latency Reversal Agents to improve reservoir targeting. The subject methods can be utilized in conjunction with any convenient methods of treating HIV or HIV latency, including methods related to immune system activation, antiretroviral therapies and/or anti-HIV agents.

A lithium air secondary battery is allowed to operate as a high-capacity secondary battery, thereby implementing high output and a large discharge capacity. A lithium air secondary battery 100 includes an air electrode 102 using oxygen in the air as a positive electrode active material, a negative electrode 104 using metallic lithium or a lithium-containing material as a negative electrode active material, and an organic electrolyte 106 placed between the air electrode 102 and the negative electrode 104, and including a lithium salt. The organic electrolyte 106 includes a crown ether compound having an azo group as an additive.

A lithium air secondary battery is allowed to operate as a high-capacity secondary battery, thereby implementing high output and a large discharge capacity. A lithium air secondary battery 100 includes an air electrode 102 using oxygen in the air as a positive electrode active material, a negative electrode 104 using metallic lithium or a lithium-containing material as a negative electrode active material, and an organic electrolyte 106 placed between the air electrode 102 and the negative electrode 104, and including a lithium salt. The organic electrolyte 106 includes a crown ether compound having an azo group as an additive.

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, R.sup.5, R.sup.6a, R.sup.6b, R.sup.6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof. ##STR00001##

The present disclosure relates to crystalline form CS3 of ozanimod hydrochloride which can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis and preparation method thereof. ##STR00001##